|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Melanotransferrin (MTf) or melanoma tumor antigen p97 is a transferrin (Tf) homolog that is found predominantly bound to the cell membrane via a glycosyl phosphatidylinositol anchor.
|
17452986 |
2007 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
|
12960359 |
2003 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Introduction of a tumor antigen-specific T cell receptor (TCR) into patient-derived lymphocytes has already exhibited promising results for the treatment of melanoma and other malignancies in clinical trials.
|
31207210 |
2019 |
|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes.
|
15386406 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive transfer of tumor-antigen-specific T(H)9 cells into both WT and Rag1(-/-) mice suppressed melanoma growth; this effect was abrogated by treatment with neutralizing antibodies to IL-9.
|
22772464 |
2012 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
|
12359758 |
2002 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported the presence of OX-40(+) T cells in head and neck cancer and melanoma, where they appear to be restricted to tumor compartments (primary tumor infiltrating lymphocytes [TILs] and draining lymph node cells) and therefore may represent the tumor antigen-specific CD4(+) T cells.
|
10930490 |
2000 |
|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators.
|
22850568 |
2012 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival.
|
29744371 |
2018 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
As tumor antigen-specific CD4+ T cells can mediate strong therapeutic anti-tumor responses in melanoma patients we set out to establish a comprehensive screening strategy for the identification of tumor-specific CD4+ T cell epitopes suitable for detection, isolation and expansion of tumor-reactive T cells from patients.
|
21152437 |
2010 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, TAP expression restores both antigen presentation and immunogenicity in A375 melanoma cells and concomitantly increases IL-12 and IFN-gamma production in tumor antigen-specific CTLs; TAP should be considered as a part of the immunotherapies for MM.
|
18385764 |
2008 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
|
29325699 |
2018 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies.
|
18157007 |
2008 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although melanoma vaccines stimulate tumor antigen-specific CD8(+) T cells, objective clinical responses are rarely observed.
|
24343228 |
2014 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently published or communicated clinical experiences and ongoing trials have used defined tumor antigen RNA transfection for prostate carcinoma and melanoma, liposome-encoated DNA transfection for breast or pancreatic cancer, adenoviral vector tumor antigen gene modification for melanoma and small cell lung cancer, and poxvirus-mediated expression of costimulatory molecules for colon carcinoma.
|
16457651 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to its tumor-restricted expression pattern and its recognition by both cytotoxic and helper T cells it constitutes a promising tumor antigen for anticancer immunotherapy, notably of malignant melanoma.
|
15570431 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study focuses on analyzing the effect of HER2 on MHC class I antigen presentation and sensitivity to tumor-antigen specific cytotoxic T lymphocytes (CTLs) in HLA-A2.1(+) melanoma cell lines.
|
20715101 |
2011 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is approximately 3.5x10(5)/ml collagen-fibrin gel in vitro and approximately 3x10(6)/ml or /g melanoma for previously published studies of ex vivo-activated adoptively transferred tumor antigen-specific CD8+ T cell killing of cognate antigen-expressing melanoma cells in established tumors in vivo.
|
20065066 |
2010 |
|
LINC01194
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Canine malignant melanoma (CMM) resembles human malignant melanoma in terms of metastatic behavior, refractoriness to standard therapy, and tumor antigen expression but it is largely unknown how CMM resembles human melanoma with regard to molecular pathogenesis and cellular signaling.
|
19949352 |
2010 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, a unique tumor antigen can be as immunogenic as the melanoma differentiation antigens but, in contrast to the latter, may be retained in all metastatic cells possibly as result of the relevant cellular function exerted by the mutated protein.
|
15695408 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human tyrosinase-derived peptide YMDGTMSQV is presented on the surface of human histocompatibility leukocyte antigen (HLA)-A*0201(+) melanomas and has been suggested to be a tumor antigen despite the fact that tyrosinase is also expressed in melanocytes.
|
10748239 |
2000 |
|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that EGF G1380A and bFGF C754G gene polymorphisms were associated with the susceptibility and prognosis of malignant melanoma, and that the polymorphisms of EGF G1380A and bFGF C754G as well as the haploid TAG increased the susceptibility of malignant melanoma.
|
28219779 |
2017 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the efficacy of melanoma DC-based immunotherapy is enhanced when tumor antigen-loaded DCs used for vaccination express cPs.
|
23934126 |
2013 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
|
11565834 |
2002 |